Case Report

Vol. 3 No. 4 (2016): European Journal of Rheumatology
DOI: https://doi.org/10.5152/eurjrheum.2016.15083

Article Sidebar

Full Text PDF
Published: Sep 3, 2019
Keywords:
Belimumab, systemic lupus erythematosus, norcardiosis, central nervous system, lupus

Main Article Content

Richard HC Lai
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA
Deborah Kim
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA
Florina Constantinescu
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA; Department of Clinical Medicine, Georgetown University Medical Center, Washington, USA

A case of central nervous system nocardiosis in a patient with lupus treated with belimumab

Main Article Content

Richard HC Lai
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA
Deborah Kim
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA
Florina Constantinescu
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA; Department of Clinical Medicine, Georgetown University Medical Center, Washington, USA

Abstract

Abstract


Belimumab was approved by the United States Food and Drug Administration in March 2011 as the first biological agent for treating active systemic lupus erythematosus (SLE). To the best of our knowledge, this is the first case report regarding a patient with SLE treated with belimumab who was diagnosed with central nervous system nocardiosis.

Belimumab was approved by the United States Food and Drug Administration in March 2011 as the first biological agent for treating active systemic lupus erythematosus (SLE). To the best of our knowledge, this is the first case report regarding a patient with SLE treated with belimumab who was diagnosed with central nervous system nocardiosis.



Article Details